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Anti-MUC1 single-chain Fv (scFv) fragments generated from the humanised antibody huHMFG1 had adequate antigen-binding
properties but very poor stability irrespective of the applied linker or domain orientation. Mutagenesis of heavy-chain framework
residue VH-71, previously described as a key residue for maintaining the CDR-H2 main-chain conformation and thus important for
antigen binding, markedly stabilised the scFv while having only a minor effect on the binding affinity of the molecule. Because of its
improved stability, the engineered fragment exhibited immunoreactivity with tumour cells even after 7 days of incubation in human
serum at 371C. It also showed, in contrast to the wild-type scFv, a concentration-dependent binding to the target antigen when
displayed on phage. When fusing the scFv to the recombinant ribonuclease rapLRI, only the fusion protein generated with the stable
mutant scFv was able to kill MUC1
þ tumour cells with an IC50 of 80nM. We expect this novel immunoenzyme to become a
promising tool for the treatment of MUC1
þ malignancies.
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The MUC1 membrane mucin glycoprotein is overexpressed in
most adenocarcinomas (Taylor-Papadimitriou et al, 1999) and
associated with poor prognosis in patients with many epithelial
cancers, including colorectal and gastric carcinoma (Utsunomiya
et al, 1998; Baldus et al, 2002). Recently, MUC1 was also found to
be overexpressed in a variety of haematological malignancies
including acute myelogenous leukaemia, chronic lymphocytic
leukaemia, and multiple myeloma (Brossart et al, 2001). Since
glycosylation of MUC1 in cancer cells is distinct from mucin
expressed in healthy tissue (Hanisch and Muller, 2000), tumour-
associated mucin represents a valuable target for diagnostic and
therapeutic approaches with monoclonal antibodies (mAbs).
Several mAbs have been raised against the highly conserved
immunogenic core region of the extracellular domain of MUC1,
which comprises tandem repeats of 20 amino acids (Gendler et al,
1988). These include mAb HMFG1 (Taylor-Papadimitriou et al,
1981), which recognises the PDTR epitope of the protein core with
high specificity (Price et al, 1990). HMFG1 becomes internalised
after antigen binding (Aboud-Pirak et al, 1988) and thus provides
a valuable tool for the selective delivery of cytotoxic agents into
tumour cells. A
90Y-HMFG1 radioimmunoconjugate was employed
in a phase I–II clinical trial in patients with ovarian cancer in an
adjuvant setting. Intraperitoneal administration of a single dose of
the reagent resulted in a 410 years long-term survival of 78% of
these patients (Epenetos et al, 2000). A multicentre, multinational,
phase III clinical trial utilising
90Y-HMFG1 for the adjuvant
treatment of women with ovarian cancer completed enrolment in
2003, and first results are expected during 2004. To overcome the
immunogenicity of mAb HMFG1 and make the antibody suitable
for repeated systemic administration, a humanised version,
designated huHMFG1, was generated by grafting the murine
antigen-binding site into human antibody frameworks (Verhoeyen
et al, 1993). huHMFG1 was shown to retain the antigen affinity and
same specificity of the rodent ancestor. Results from a recently
completed radioimmunoimaging study in breast cancer patients
(Al-Yasi et al, 2002) showed the specific binding of huHMFG1 to
tumour tissues. The humanised antibody is currently being
evaluated as a therapeutic agent in a phase I clinical trial in
patients with metastatic breast cancer. For many clinical applica-
tions, such as radioimmunoimaging, radioimmunotherapy, or
administration of recombinant cytotoxic fusion proteins, the
employment of small antigen-binding fragments such as single-
chain Fv (scFv) antibodies or multivalent derivatives may have
advantages over the use of antibodies in the IgG format. ScFv
fragments penetrate solid tumour tissue more efficiently (Yokota
et al, 1992) and are rapidly cleared from the circulation (Milenic
et al, 1991). To exploit these advantages, huHMFG1 was
reformatted into an scFv fragment. Although this construct
exhibited appropriate antigen binding, its half-life was o2h when
incubated in human serum at 371C. Low biophysical stability of
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sscFv fragments was shown to be associated with the failure to
localise to xenografted tumour tissue in immunodeficient mice
(Willuda et al, 1999). Thus, for clinical applications, sufficient
stability of scFv fragments is of paramount importance.
The aim of this study was to generate a humanised anti-MUC1
scFv with sufficient antigen-binding and stability properties as
required for clinical applications. Here we show that mutagenesis
of human antibody framework 3 residue VH-71Arg to the
corresponding murine donor antibody site alanine (VH-71Arg-
Ala) dramatically increased the stability of the humanised scFv
while only having a minor impact on the affinity of the molecule.
As a consequence of its improved stability, only the robust mutant
scFv genetically fused to the ribonuclease rapLRI mediated
cytotoxicity towards tumour cells and recognised its native target
antigen when displayed on phage. Our results indicate that
framework residue VH-71 plays a critically important role in
providing intrinsic stability to antibody heavy-chain variable
domains.
MATERIALS AND METHODS
Identification of unusual framework residues
To identify unusual residues within the human variable domain
framework regions (FRs), which could possibly influence the
structural integrity of the grafted antigen-binding site of the
humanised scFv antibody, we aligned its amino-acid sequence to
sequence reference templates. Mismatching ‘key residues’ (Chothia
et al, 1989) between the frameworks of the murine donor antibody
sequence and the human acceptor antibody sequence were
identified and canonical-class assignments of the donor antibody
complementarity determining regions (CDRs), L1–L3, H1, and H2,
respectively, were determined by screening the sequence against
sequence templates of antibody repertoires (Martin and Thornton,
1996) at http://www.bioinf.org.uk/. Furthermore, uncommon
residues at the VH/VL interface (Chothia et al, 1985) of the
humanised scFv with a potential to compromise interdomain
stability of the molecule were inspected.
Generation of wild-type scFv huHMFG1 and scFv mutants
To generate a humanised scFv, the variable light chain and the
variable heavy chain of huHMFG1 were PCR amplified from
plasmids pAS1 and pAS2 (Dr R Young, Antisoma Research Ltd),
containing the complete light chain and heavy chain of the
humanised antibody, respectively. Single-chain Fv variants with
flanking NcoI and BamHI restriction sites were generated by PCR
in either domain orientation and with different linker peptides
(Table 1). Mutations were introduced by oligonucleotide directed
mutagenesis and overlap extension PCR techniques as described
elsewhere (Ho et al, 1989). Fragments were cloned into vector
pHOG21 (Kipriyanov et al, 1996) for the expression of soluble
protein.
Periplasmic expression and purification of scFv fragments
Single-chain Fv fragments were expressed as soluble protein in the
periplasm of the Escherichia coli strain TG1 (Stratagene, La Jolla,
CA, USA) and purified by immobilised metal chelate affinity
chromatography (IMAC) and size-exclusion chromatography as
described previously (Arndt et al, 2003). Concentrations of
purified scFvs were determined spectrophotometrically from the
absorbance at A280nm using the extinction coefficient e1mgml
 1
¼ 1:67:
Generation, expression, and purification of
scFv-ribonuclease fusion proteins
Expression vector pBJR-2 was generated by cloning the PCR-
amplified gene encoding the amphibian ribonuclease rapLRI
(Chen et al, 2000) and G4S spacer with flanking NcoI and PvuII
restriction sites into the expression vector pHOG21 (Kipriyanov
et al, 1996). RapLR1-G4S-4.9M was obtained by ligating the PvuII–
BamHI fragment of scFv 4.9M into the PvuII–BamHI-restricted
pBJR-2 vector (Figure 1). The correct size and sequence of the
insert were analysed by restriction digest and DNA sequencing,
respectively.
E. coli TG1 bacteria transformed with the plasmid encoding the
rapLR1-G4S-4.9M gene were grown at 371C overnight in 50ml 2YT
media containing 200mgml
 1 ampicillin and 2% glucose. Bacteria
were diluted into 4l 2YT media containing 200mgml
 1 ampicillin
and grown at 371Ct oa nO D 600 of 1.0. Protein expression was
induced by adding IPTG to a final concentration of 1.0mM to the
culture and incubation continued at 261C for 16–18h. The bacteria
were centrifuged at 10000g for 45min at 41C. The fusion protein
was isolated from inclusion bodies, denatured, renatured, and
dialysed as described previously (Newton et al, 1996). The
extensively dialysed protein solution was applied to a 40ml CM-
Sephadex C-50 column (Pharmacia Biotech Inc., Piscataway, NJ,
USA) equilibrated with 20mM Tris-HCl, pH 7.5, containing 10%
glycerol. The fusion protein was eluted with equilibration buffer
Table 1 huHMFG1 scFv variants
Clone
VH71R VH71A Orientation
Linker
length Linker sequence
17W
a 17M
a VL–VH 17 ASSGGGGSGGGGSGGSA
22W 22M VL–VH 22 ASSGGGGSGGGGSGGSAGGGGS
4.10W 4.9M VH–VL 15 GGGGSGGGGSGGGGS
aW¼wild type; M¼mutant.
Figure 1 Schematic representation of fusion protein expression vector
pBJR-2. Ap
R, ampicillin resistance gene; ColE1, origin of DNA replication;
c-myc, sequence encoding the c-myc epitope; His6, hexa-histidine encoding
sequence; P/O, lac wild-type promoter/operator; rbs, ribosome-binding
site; pelB, signal peptide sequence of bacterial pectate lyase; VH, variable
heavy chain; VL, variable light chain; rapLR1, Rana pipiens liver ribonuclease
1; H71, framework 3 residue 71; G4S, spacer connecting the ribonuclease
with the scFv; (G4S)3, linker connecting the variable domains. Restriction
sites for cloning are indicated.
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scontaining 1.0 M NaCl. The protein solution was diluted 10-fold
with 50mM NaOAc, pH 5.0, immediately applied to a 2ml SP-
Sepharose column (Pharmacia Biotech Inc.) and eluted with a
200ml linear NaCl gradient (0.1–0.7 M)i n5 0m M NaOAc, pH 5.0.
Cell-binding assays
Specific binding of scFv constructs was determined by flow
cytometry using the human MUC1
þ cell lines MCF7 (ATTC,
Manassas, VA, USA) and SKOV-3 (ATTC), and mouse myeloma B-
cell line Sp2/0-Ag14 (ATTC) and human T-cell line Jurkat (ATTC)
as a negative control. For the determination of antigen-binding
affinity constants (Kd), MCF7 cells were used. Staining of antibody
fragments and affinity measurements were performed as described
previously (Benedict et al, 1997). Stained cells were analysed on a
FACScan Flow Cytometer (BD Bioscience, San Jose, CA, USA), and
median fluorescence intensity (MFI) was calculated using the
CellQuestt software (BD Bioscience). Background flourescence
was subtracted. Equilibrium constants were determined by using
the Marquardt–Levenberg algorithm for nonlinear regression with
the GraphPad Prism version 3.0a for Macintosh (GraphPad
Software, San Diego, CA, USA).
Cytotoxicity assay
Cytotoxicity of scFv-RNase fusion proteins towards target cells was
analysed by a protein synthesis inhibition assay. In all, 2.5 10
3
MCF7 cells in a volume of 100ml were plated in each well of a 96-
well plate 24h before treatment and the assay performed according
to standard procedures as described previously (Newton et al,
1996). Experiments were performed at least twice. The concentra-
tion of fusion protein test sample that inhibits protein synthesis by
50% (¼IC50) was determined from semilogarithmic plots as
percentage of [
14C]leucine incorporation into mock-treated cells.
Generation of computer homology models
Three homologous models of scFv 4.9M were generated based on
existing structures of scFv proteins (Berman et al, 2000) with either
an Arg or an Ala at position VH-71 located in the heavy-chain FR 3.
Two forms of huHMFG1-Arg71 with distinct conformations in
their CDR-H1 (residues 31–35) and CDR-H2 (residues 50–65)
regions were modelled based on observed conformations in scFv
structures with an Arg at position VH-71. In one form, the side
chain of VH-71Arg is exposed to the surface of the protein as
observed in PDB entry 1NQB (Pei et al, 1997), whereas in the
other, this side chain is buried between motifs CDR-H1 and CDR-
H2 as in PDB entry 2FBJ (Suh et al, 1986). Only one form of scFv
huHMFG1-Ala71 was modelled because all the scFv structures with
an Ala at VH-71 exhibit the same conformation as in PDB entry
1EO8 (Fleury et al, 2000).
Model-1 with exposed VH-71Arg side chain was built based on a
trimeric antibody (PDB 1NQB; Pei et al, 1997) showing 63%
sequence similarity to scFv huHMFG1. The starting model was
constructed with 1NQB fragments C121–C233 of the primary
molecule and C1–C120 of a symmetry mate. Mutations were
performed according to the sequence of scFv huHMFG1. Model-2
with the buried VH-71Arg side chain was built based on the crystal
structure of antibody J539 (PDB entry 2FBJ; Suh et al, 1986). The
sequence similarity of J539 with scFv huHMFG1 is very low (54%).
Hence, fragments FR3 (VH-66-94) and CDR-H3 (VH-95-102) and
the VL region were taken from Model-1 followed by the
introduction of corresponding mutations. Model-3 with VH-
71Ala was built based on PDB entry 1EO8 (Fleury et al, 2000).
The VH and VL sequences of 1EO8 are 72 and 26% identical with
those of huHMFG1, respectively. Mutations were performed in the
VH region; the VL region was taken from Model-1. Modelling was
performed using the graphics program O (Jones and Kjeldgaard,
1997), the models were optimised using the energy minimisation
procedure embedded in the program CNS (Bru ¨nger and Rice,
1997), and the illustration was made using programs Bobscript
(Esnouf, 1997) and Raster3D (Merritt and Bacon, 1997).
Expression of scFv fragments on phage
Wild-type sequence scFv 4.10W and mutant scFv 4.9M encoding
genes (Table 1) or wild-type scFv 17W with randomised linker
peptide sequence were cloned into phagemid pCANTAB-5
(Amersham Pharmacia, Uppsala, Sweden) after the introduction
of flanking restriction sites SfiI/NotI by PCR. Phagemid virions
were prepared essentially according to standard methods as
described (Sambrook et al, 1989; Marks et al, 1991).
Phage ELISA
The ability of phage-displayed scFvs for recognising the target
antigen MUC1 was determined by whole-cell ELISA with MCF7
cells. In all, 1 10
4cellswell
 1 were seeded in a 96-well plate (Nunc
Nalgene, Roskilde, Denmark) and grown in DMEM medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum until 60–70% confluent. Cells were fixed by adding
paraformaldehyde diluted in PBS to a final concentration of 1%
and incubated for 10min at room temperature. After washing with
PBS, a serial dilution of purified scFv phagemid virion or M13KO7
helper phage alone (Invitrogen) was added to the cells. Plates were
gently shaken for 2h at 371C. After 6  washing with PBS/Tween-
20 0.02%, rabbit anti-M13-HRP polyclonal antibody (1:5000;
Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) was
added. The mixture was incubated at 371C for 1h. Cells were
washed with PBS and bound phage scFvs were detected using
ABTS (Sigma Chemicals, Saint Louis, MO, USA) as a substrate.
After 30min incubation, absorbance was read with an ELISA
reader (Bio-Tek Instruments Inc., Winooski, VT, USA) at 405nm.
Biophysical stability
Single-chain Fv fragments were incubated at 371C in 90% human
serum at a concentration of 20mgml
 1 for up to 7 days. Samples
were taken at different time points and stored at –201C. Binding
activity of the samples to MUC1
þ MCF7 cells was determined by
flow cytometry. The MFI was determined as described above.
Temperature-dependent degradation of monomeric scFvs was
determined by incubation of samples at 371C in 90% PBS at a
concentration of 20mgml
 1 for 1h, followed by analytical gel
filtration on a calibrated Superdex 75 HR10/30 column (Amersham
Pharmacia Biotech Inc.)
RESULTS
Generation and characterisation of wild-type sequence
scFvs
In order to generate a small antigen-binding molecule to be used as
a building block for the subsequent construction of recombinant
fusion proteins, the variable domains of light and heavy chains of
the humanised mAb huHMFG1 (Verhoeyen et al, 1993) were
recloned into a VL–VH oriented scFv format, separated by a
synthetic 17-amino-acid linker peptide (clone 17W, Table 1).
Although the scFv showed specific binding to MUC1
þ tumour
cells, its half-life in human serum at 371C was less than 2h (data
not shown). To improve the stability of the wild-type scFv
molecule by alteration of the linker peptide, this region was
randomised by PCR and the resulting scFv fragments were
recloned into a phagemid vector for display on phage. However,
no clones could be enriched after panning the generated scFv
library on MUC1
þ MCF7 cells. These results indicate that the
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slinker-randomised scFvs were not displayed in a conformation for
binding to native antigen. To further investigate whether the VL–
VH connecting linker peptide length or domain orientation
accounted for the poor stability of the wild-type scFv, two further
linker variants, 22W and 4.10W, were generated (Table 1). Both
constructs retained specific binding to MUC1
þ tumour cells but
did not show an increase in their half-lives, indicating that
changing the domain orientation or linker length was not sufficient
to increase the stability of the molecules.
Analysis of huHMFG1 variable domain wild-type sequence
The amino-acid sequence of the humanised scFv antibody was
analysed as described in Materials and Methods. We identified VH-
71, previously described as a ‘key residue’ for the CDR-H2 main-
chain conformation (Chothia et al, 1989; Tramontano et al, 1990),
to be potentially critical for maintaining the structural integrity of
the grafted antigen-binding site of the wild-type scFv fragment. To
study the effects of framework residue VH-71 on antigen-binding
and stability properties of the humanised scFvs, three mutant
variants were generated by replacing arginine in the human
framework 3 sequence with the murine donor antibody residue
alanine (clones 17M, 22M, 4.9M; Table 1).
Effects of VH-71Arg-Ala mutation on stability and
specificity of scFv fragments
For initial characterisation, the mutant variant scFvs (clones 17M,
22M, 4.9M; Table 1) were IMAC purified. In flow cytometry, all
three variants showed specific binding to MUC1
þ MCF7 cells. To
assess the global stability, the engineered scFvs were incubated in
human serum at 371C for 12h. The half-live of mutant 17M was not
increased when compared with the corresponding wild-type scFv
17W (data not shown). In contrast, immunoreactivity with tumour
cells at this time point was observed for mutants 22M and 4.9M,
respectively. Monomers of scFvs 22M and 4.9M as well as their
wild-type counterparts (clones 22W and 4.10W, respectively) were
subsequently separated from higher molecular weight species by
size-exclusion chromatography. Both purified wild-type and
mutant scFvs exhibited specific binding towards MUC1
þ tumour
cells as shown in Figure 2 for the example of constructs in the VH-
VL orientation. The stability of 22M and 4.9M monomers was
determined by incubation of purified proteins in human serum at
371C for various time periods. As demonstrated in Figure 3, both
mutant scFvs exhibited dramatically improved stability when
compared with the corresponding wild-type constructs. Never-
theless, both constructs showed a substantial decline in cell-
binding activity within the first hour of serum incubation (4.9M,
40%; 22M, 51%) although they retained specific binding to tumour
cells even after 7 days of serum incubation (Figure 3). To
determine whether this phenomenon was induced by exposure of
the scFvs to elevated temperature or to serum components, mutant
scFv 4.9M was incubated in PBS for 1h at 371C and binding
activity to MCF7 cells was analysed by flow cytometry. As shown in
Figure 4A, the median flourescence intensity dropped to a similar
level whether the scFv was incubated in human serum or PBS at
371C. Analytical size-exclusion chromatography revealed no
degradation of the monomeric protein at this time point
(Figure 4B), suggesting that the initial decrease in immunoreac-
tivity was due to reduced binding affinity caused by exposure of
the scFv to the elevated temperature.
Effects of VH-71Arg-Ala mutation on affinity of scFv
fragments
Binding affinity constants for the wild-type scFvs 22W and 4.10W,
and mutant variants 22M and 4.9M (Table 1) were determined. As
shown in Table 2, mutagenesis of VH-71Arg -Ala had only a small
effect on binding affinity of the constructs to the target cells
irrespective of the variable domain orientation and linker. Since a
temperature-dependent decrease in immunoreactivity of the
mutant scFv fragments with rapid onset was observed in the
stability assay, the binding constant of the construct with the
tightest antigen binding (clone 4.9M) was determined again after
preincubation in PBS for 1h at 371C. This short exposure to
physiological body temperature resulted in a 1.9-fold decrease in
antigen-binding affinity (Table 2).
Computer homology modelling
In order to understand the structural consequences of the VH-
71Arg-Ala mutation, we analysed the impact of this mutation on
the conformation and relative position of antigen-binding loops
(CDR-H1 and CDR-H2) and calculated the buried surface area of
the interface between the two motifs CDR-H1 and CDR-H2 for the
three huHMFG1 models. As shown in Figure 5, the backbone
conformation of CDR-H1 is virtually the same in all three models,
whereas the conformation of CDR-H2 is significantly different.
However, it appears that the buried surface area between motifs
Figure 2 Specific binding activity of mAb huHMFG1 and derived scFv
fragments 4.10W and 4.9M. Flow cytometric analysis revealed for all
purified antibodies binding to breast carcinoma cell line MCF7 and ovarian
carcinoma cell line SKOV3, no binding was detected for T-cell lymphoma
cell line Jurkat and mouse myeloma B-cell line SP2/0-AG14. Cells stained
with secondary antibodies only were used as negative control.
Figure 3 Serum stability of scFv fragments. Immunoreactivity of wild-
type scFvs 4.10W and 22W, and mutant variant scFvs 4.9M and 22M with
MCF7 cells was measured by flow cytometry after incubating the constructs
at 371C in human serum for various time periods. Binding activity is shown
as per cent of the maximal MFI at time point zero.
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sCDR-H1 and CDR-H2 is dictated by the identity of residue VH-71
but not the conformation of the two motifs: For the VH-Ala71
model, it is 481A ˚2, which is significantly larger than for the two
VH-Arg71 models (384 and 398A ˚2 in Model-1 and Model-2,
respectively).
Expression of scFv variants on phage
To examine the possibility of using the humanised scFv antibody
as a template to select entire human fragments from phage display
libraries by chain shuffling (Marks et al, 1992), both wild-type
sequence scFv 4.10W and mutant 4.9M were recloned in a
phagemid vector for display on phage. The titre of the
concentrated phage stock was 1 10
12 1 10
13CFUml
 1.I n
whole-cell ELISA, only the displayed mutant scFv 4.9M showed
reactivity with MUC1
þ tumour cells in a concentration-dependent
manner (Figure 6), indicating that the wild-type scFv was not
appreciably expressed on phage.
Effect of VH-71Arg-Ala mutation on cytotoxic properties
of a recombinant immunoenzyme
To evaluate the stabilised humanised scFv antibody as a targeting
moiety for the selective delivery of cytotoxic agents into tumour
cells, a recombinant fusion protein comprising the recombinant
ribonuclease rapLR1 and scFv 4.9M was made. This construct
could be purified to homogeneity and was active in killing MCF7
cells with an IC50 of 80nM (Figure 7). The cytotoxic activity of
rapLR1 in the fusion protein configuration was increased
approximately 18-fold (IC50 for native rapLR1, 1500nM). In
Figure 4 Effect of temperature on immunoreactivity and stability of
mutant scFv 4.9M. (A) Binding was analysed by flow cytometry before and
after incubation at 371C for 1h either in PBS or human serum. MCF7 cells
stained with secondary antibodies were used as negative control.
(B) Analytical size-exclusion FPLC on a calibrated Superdex 75 column
was performed before (left panel) and after (right panel) incubation of
20mgml
 1 scFv in PBS at 371C for 1h. Monomeric protein eluted at
12.5ml at a flow rate of 0.3mlmin
 1.
Figure 5 Homology modelling. The models shown as worm diagrams
illustrate the influence of residue VH-71 on the conformation of CDR-H1
and CDR-H2. Model-1 with the side chain of Arg71 exposed to the surface
of the VH domain is shown in red, Model-2 with Arg71 buried between
motifs CDR-H1 and CDR-H2 in green, and Model-3 with Ala71 in blue.
Table 2 Binding affinity constants of mAb, wild-type, and mutant scFv
fragments
scFv
mAb huHMFG1 22W 4.10W 22M 4.9M
Kd (nM)
a 2.3 199 113 160 103
Kd (nM)
b 195
aAffinity determined at room temperature.
bAffinity determined after 1h incubation
in PBS at 371C.
Figure 6 Whole-cell ELISA of phage-displayed wild-type and mutant
scFv. Various concentrations of 4.10 wild-type scFv phage, 4.9 mutant scFv
phage, or control M13KO7 helper phage were incubated with MCF7 cells
subconfluently grown in 96-well plates for 2h at 371C. Bound phages were
detected with anti-M13-HRP polyclonal antibody as described in Materials
and Methods.
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scontrast, a fusion protein comprising rapLRI and wild-type scFv
17W could not be purified to homogeneity and did not exhibit any
cytotoxic activity towards MUC1
þ tumour cells.
DISCUSSION
The aim of this study was to generate a functional scFv molecule
from the clinically established humanised anti-MUC1 mAb
huHMFG1. For clinical applications, scFv molecules must have
sufficient affinity for the target antigen and remain stable in the
human body for at least several hours. Failure to meet these
criteria was shown to result in insufficient enrichment of scFv
molecules in xenografted solid tumours in immunodeficient mice
(Adams et al, 1998; Willuda et al, 1999), thus hampering future
clinical applications.
We initially generated an scFv molecule from the variable
domains of the humanised mAb huHMFG1 that specifically bound
to MUC1
þ tumour cells but did not exhibit sufficient stability. It
has been reported that the length and amino-acid composition of
scFv linker peptides can influence both the stability and solubility
of scFv fragments (Robinson and Sauer, 1998). To assess whether
the linker peptide or domain orientation may have contributed to
the poor stability of the wild-type sequence scFvs, we system-
atically varied linker length, domain orientation, and eventually
amino-acid composition of the linker by a phage display approach.
None of these approaches, however, resulted in the generation of a
stable molecule.
Sequence analysis of the humanised wild-type scFv revealed
framework 3 residue VH-71Arg to be potentially critical for
disrupting the structural integrity of the grafted murine antigen-
binding site. Site VH-71 is located at one of the two corners of the
inner faces of the b-sheets and can be exposed to the solvent
through the twist and coil of the b-sheet (Chothia et al, 1998). It is
one of a set of sites forming the ‘Vernier’ zone (Foote and Winter,
1992). The ‘Vernier’ zone comprises a layer of framework residues
that support antigen-binding loop conformations and their relative
dispositions and has therefore been suggested to play an important
role in fine-tuning the fit of an antibody to antigen (Foote and
Winter, 1992). Residues with small side chains at position VH-71
such as an alanine provide a cavity for orienting the CDR-H2 loop
in close proximity to CDR-H1 (Tramontano et al, 1990; Xiang et al,
1995). Disruption of the cavity by replacing a small side chain with
bulkier ones was shown to separate the antigen-binding loops
CDR-H1 and CDR-H2 from each other and expose the CDR-H2
loop residue VH52a to the surface (Tramontano et al, 1990). This
resulted in a 12-fold decrease in the binding affinity of a chimeric
antibody with specificity for the TAG72 antigen (Xiang et al, 1995),
a 45-fold lower affinity of a humanised anti-ErB2 antibody for
binding to breast cancer cells (Carter et al, 1992), and a complete
loss of antigen binding of a humanised anti-alpha 4 integrin
antibody (Leger et al, 1997). In contrast, crystal structures of
several mutants of a humanised anti-lysozyme Fv fragment with
different side-chain sizes of VH-71 revealed no conformational
adjustment of CDR-H2 relative to CDR-H1 in either the ligand-free
form or in complex with lysozyme (Holmes et al, 2001). In
addition, VH-71 was reported to be of minor importance for
antigen binding of a humanised anti-CD18 antibody (Hsiao et al,
1994). In this study, we also observed minor effects on antigen-
binding properties of the VH-71Arg-Ala mutant scFv. Taken
together, these data indicate that the residue type at VH-71 alone
may not invariantly fix the spatial orientation of CDR-H1/CDR-H2
and thus may not always play an important role in influencing
antigen-binding properties of an antibody. Surprisingly however,
the mutant scFv fragments exhibited a 1.9-fold decline in antigen-
binding affinity after short exposure to physiological body
temperature. This phenomenon could be observed after preincu-
bation at 371C in either human serum or PBS. Because protein
degradation could be excluded by analytical size-exclusion
chromatography, it is conceivable that this phenomenon most
likely occurred through a temperature-dependent conformational
alteration of the antigen-binding site of the molecule.
The stabilised monovalent scFv antibody 4.9M exhibited 45-fold
reduced binding affinity when compared with the parental
humanised IgG. As shown for bivalent diabodies derived from
scFvs with different affinities for binding to ErB2, the increment in
binding affinity upon dimerisation was greatest for the lowest
affinity scFv (65-fold) and least for the highest affinity scFv (7.7-
fold) (Nielsen et al, 2000). In keeping with this observation, a
phage display library-selected Fab fragment with low affinity for
binding to MUC1 exhibited an even 160-fold improved apparent
Kd after being re-engineered into a bivalent fully human IgG
molecule (Henderikx et al, 2002). Similarly, reformatting the
mutant scFv 4.9M characterised in this study into a bivalent
diabody resulted in a molecule with tight antigen binding (Kd 8n M;
J Krauss, unpublished results). These data indicate that the
moderate binding affinity of the scFv and derived fusion proteins
can be markedly enhanced by generating bivalent derivatives.
Although residue VH-71 has been described as a major
determinant for the CDR-H1 and CDR-H2 conformation and thus
important for antigen binding, we are not aware of any reports
indicating that this site also has an impact on the stability of
antibody scFv fragments. As our data clearly show, the replace-
ment of the bulky side-chain residue arginine by alanine at VH-71
dramatically increased the stability of the scFv fragments
irrespective of the domain orientation. As a result, both mutant
variants exhibited immunoreactivity with tumour cells even after 7
days of incubation in human serum at 371C. The magnitude of
stability improvement was surprising since the above-described
location of VH-71 and its structural role did not necessarily suggest
this residue to be of such critical importance for providing stability
to the humanised scFv fragment. To study the consequences of the
VH-71Arg-Ala mutation on the scFv structure, three computer
homology models were generated. The models revealed the buried
surface area between CDR-H1 and CDR-H2 to be significantly
larger (approximately 20%) in the VH-71Ala variant, resulting in a
markedly stabilised VH domain of the mutant scFvs.
Since previous attempts to display the wild-type scFv huHMFG1
on phage were unsuccessful, we analysed whether this failure was
caused by the insufficient stability of the fragment. Indeed, our
data show that only the stable mutant scFv recognised native
Figure 7 Cytotoxicity of rapLR1-G4S-4.9M fusion protein. Various
concentrations of the fusion protein or RNase alone were incubated with
MCF7 cells for 3 days and protein synthesis measured by [
14C]leucine
incorporation as described in Materials and Methods. Protein synthesis
inhibition of target cells is expressed as percentage of protein synthesis to
buffer-treated control cells.
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santigen, indicating that appropriate intrinsic stability of the
molecule was absolutely required for being displayed on phage
in correctly folded conformation. The possibility to express the
mutant scFv on phage paves the way for generating entire human
anti-MUC1 fragments by chain shuffling of a human phage display
library.
Ribonucleases have become established potent anticancer
reagents within the last few years. In a recently conducted
multicentre phase II clinical trial, a ribonuclease very closely
related to rapLRI used in this study, Ranpirnase (onconase), was
administered to more than 100 patients with unresectable
malignant mesothelioma (Mikulski et al, 2002). Overall response
rates of about 50% were achieved. When given intravenously on a
weekly basis, in some cases for more than 3 years, onconase was
remarkably well tolerated in the vast majority of patients, with no
appreciable adverse side effects attributed to immunogenicity of
the reagent. Factors accounting for the low immunogenic potential
of onconase may include its considerable sequence homology to
human ribonucleases and the small size, basicity, and lack of
glycosylation of the molecule. RapLRI, as a very close homologue
of onconase, might therefore not be expected to exhibit significant
immunogenicity in humans despite its amphibian origin. We have
previously shown that rapLRI exhibits cytotoxic properties
comparable to those of onconase and that its potency could be
dramatically increased both in vitro and in vivo after conjugation
to mAbs (Hursey et al, 2002). In contrast to onconase, rapLRI does
not require an N-terminal pyroglutamate in order to retain its full
activity (Hursey et al, 2002), suggesting this ribonuclease to
represent a most promising candidate for fusion with small-sized
antibody fragments. By showing that only a recombinant rapLRI
antibody fusion protein made with a stable scFv could be purified
to homogeneity and exhibited potent cytotoxic activity, this study
clearly illustrates the importance of addressing the stability
properties of scFv fragments intended to be used for the generation
of recombinant fusion proteins.
Since most recent results indicate strong in vivo activity of an
immunoconjugate comprising the parental humanised mAb
huHMFG1 and rapLRI in tumour-xenotransplanted immunodefi-
cient mice (DL Newton, unpublished results), we believe that
the novel, stable immunoenzyme derivative merits further
investigation as a therapeutic agent for patients with MUC1
þ
malignancies.
ACKNOWLEDGEMENTS
We thank D Ruby and M Hursey for excellent technical assistance
and Dr E Sausville for his continued interest and support. The
content of this publication does not necessarily reflect the views or
policies of the Department of Health and Human Services, nor
does mention of trade names, commercial products, or organisa-
tions imply endorsement by the US Government. This project has
been funded in whole or in part with Federal Funds from the
National Cancer Institute, National Institutes of Health, under the
contract number N01-CO-12400, and grants from the Deutsche
Krebshilfe/Dr Mildred-Scheel-Stiftung Grant D/00/39301 (to JK),
and Deutsche Akademie der Naturforscher Leopoldina Grant
BMBF-LPD 9901/8-33 (to MAEA).
REFERENCES
Aboud-Pirak E, Sergent T, Otte-Slachmuylder C, Abarca J, Trouet A,
Schneider YJ (1988) Binding and endocytosis of a monoclonal antibody
to a high molecular weight human milk fat globule membrane-associated
antigen by cultured MCF-7 breast carcinoma cells. Cancer Res 48: 3188–
3196
Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner
LM (1998) Increased affinity leads to improved selective tumor delivery
of single-chain Fv antibodies. Cancer Res 58: 485–490
Al-Yasi AR, Carroll MJ, Ellison D, Granowska M, Mather SJ, Wells CA,
Carpenter R, Britton KE (2002) Axillary node status in breast cancer
patients prior to surgery by imaging with Tc-99m humanised anti-PEM
monoclonal antibody hHMFGI. Br J Cancer 86: 870–878
Arndt MA, Krauss J, Schwarzenbacher R, Vu BK, Greene S, Rybak SM
(2003) Generation of a highly stable, internalizing anti-CD22 single-chain
Fv fragment for targeting non-Hodgkin’s lymphoma. Int J Cancer 107:
822–829
Baldus SE, Monig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S, Zilkens G,
Madejczik B, Thiele J, Schneider PM, Holscher AH, Dienes HP (2002)
Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-
Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma.
Histopathology 40: 440–449
Benedict CA, MacKrell AJ, Anderson WF (1997) Determination of the
binding affinity of an anti-CD34 single-chain antibody using a novel,
flow cytometry based assay. J Immunol Methods 201: 223–231
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids
Res 28: 235–242
Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S,
Kanz L, Buhring HJ, Brugger W (2001) The epithelial tumor antigen
MUC1 is expressed in hematological malignancies and is recognized by
MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61: 6846–6850
Bru ¨nger AT, Rice LM (1997) Crystallographic refinement by simulated
annealing: methods and applications. Methods Enzymol 277: 243–269
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL,
Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of
an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad
Sci USA 89: 4285–4289
Chen S, Le SY, Newton DL, Maizel Jr JV, Rybak SM (2000) A gender-
specific mRNA encoding a cytotoxic ribonuclease contains a 30 UTR of
unusual length and structure. Nucleic Acids Res 28: 2375–2382
Chothia C, Gelfand I, Kister A (1998) Structural determinants in the
sequences of immunoglobulin variable domain. J Mol Biol 278: 457–479
Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff
S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM,
Poljak RJ (1989) Conformations of immunoglobulin hypervariable
regions. Nature 342: 877–883
Chothia C, Novotny J, Bruccoleri R, Karplus M (1985) Domain association
in immunoglobulin molecules. The packing of variable domains. J Mol
Biol 186: 651–663
Epenetos AA, Hird V, Lambert H, Mason P, Coulter C (2000) Long term
survival of patients with advanced ovarian cancer treated with
intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10: 44–46
Esnouf RM (1997) An extensively modified version of MolScript that
includes greatly enhanced coloring capabilities. J Mol Graphics Model 15:
112–113 132–134
Fleury D, Daniels RS, Skehel JJ, Knossow M, Bizebard T (2000) Structural
evidence for recognition of a single epitope by two distinct antibodies.
Proteins 40: 572–578
Foote J, Winter G (1992) Antibody framework residues affecting the
conformation of the hypervariable loops. J Mol Biol 224: 487–499
Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988)
A highly immunogenic region of a human polymorphic epithelial mucin
expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:
12820–12823
Hanisch FG, Muller S (2000) MUC1: the polymorphic appearance of a
human mucin. Glycobiology 10: 439–449
Henderikx P, Coolen-van Neer N, Jacobs A, van der Linden E, Arends JW,
Mullberg J, Hoogenboom HR (2002) A human immunoglobulin G1
antibody originating from an in vitro-selected Fab phage antibody binds
avidly to tumor-associated MUC1 and is efficiently internalized. Am J
Pathol 160: 1597–1608
Holmes MA, Buss TN, Foote J (2001) Structural effects of framework
mutations on a humanized anti-lysozyme antibody. J Immunol 167:
296–301
VH-71 and stability of a humanised anti-MUC1 scFv
J Krauss et al
1869
British Journal of Cancer (2004) 90(9), 1863–1870 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sHo SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-directed
mutagenesis by overlap extension using the polymerase chain reaction.
Gene 77: 51–59
Hsiao KC, Bajorath J, Harris LJ (1994) Humanization of 60.3, an anti-CD18
antibody; importance of the L2 loop. Protein Eng 7: 815–822
Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM
(2002) Specifically targeting the CD22 receptor of human B-cell
lymphomas with RNA damaging agents: a new generation of therapeu-
tics. Leuk Lymphoma 43: 953–959
Jones TA, Kjeldgaard M (1997) Electron-density map interpretation.
Methods Enzymol 277: 173–208
Kipriyanov SM, Kupriyanova OA, Little M, Moldenhauer G (1996) Rapid
detection of recombinant antibody fragments directed against cell-
surface antigens by flow cytometry. J Immunol Methods 196: 51–62
Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha
J, Jones ST, Fritz LC, Bendig MM (1997) Humanization of a mouse
antibody against human alpha-4 integrin: a potential therapeutic for the
treatment of multiple sclerosis. Hum Antibodies 8: 3–16
Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G
(1992) By-passing immunization: building high affinity human anti-
bodies by chain shuffling. Biotechnology (NY) 10: 779–783
Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD,
Winter G (1991) By-passing immunization. Human antibodies from V-
gene libraries displayed on phage. J Mol Biol 222: 581–597
Martin AC, Thornton JM (1996) Structural families in loops of homologous
proteins: automatic classification, modelling and application to anti-
bodies. J Mol Biol 263: 800–815
Merritt EA, Bacon DJ (1997) Raster3D: photorealistic molecular graphics.
Methods Enzymol 277: 505–524
Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H,
Mittelman A, Panella T, Puccio C, Fine R, Shogen K (2002) Phase II trial
of a single weekly intravenous dose of ranpirnase in patients with
unresectable malignant mesothelioma. J Clin Oncol 20: 274–281
Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF,
Whitlow M, Snoy P, Schlom J (1991) Construction, binding properties,
metabolism, and tumor targeting of a single-chain Fv derived from
the pancarcinoma monoclonal antibody CC49. Cancer Res 51:
6363–6371
Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM (1996) Angiogenin
single-chain immunofusions: influence of peptide linkers and spacers
between fusion protein domains. Biochemistry 35: 545–553
Nielsen UB, Adams GP, Weiner LM, Marks JD (2000) Targeting of bivalent
anti-ErbB2 diabody antibody fragments to tumor cells is independent of
the intrinsic antibody affinity. Cancer Res 60: 6434–6440
Pei XY, Holliger P, Murzin AG, Williams RL (1997) The 2.0-A ˚ resolution
crystal structure of a trimeric antibody fragment with noncognate VH-
VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci
USA 94: 9637–9642
Price MR, Hudecz F, O’Sullivan C, Baldwin RW, Edwards PM, Tendler SJB
(1990) Immunological and structural features of the protein core of
human polymorphic epithelial mucin. Mol Immunol 62: 795–802
Robinson CR, Sauer RT (1998) Optimizing the stability of single-chain
proteins by linker length and composition mutagenesis. Proc Natl Acad
Sci USA 95: 5929–5934
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning. A Laboratory
Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
Suh SW, Bhat TN, Navia MA, Cohen GH, Rao DN, Rudikoff S, Davies DR
(1986) The galactan-binding immunoglobulin Fab J539: an X-ray
diffraction study at 2.6-A ˚ resolution. Proteins 1: 74–80
Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) MUC1 and
cancer. Biochim Biophys Acta 1455: 301–313
Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL,
Bodmer WF (1981) Monoclonal antibodies to epithelium-specific
components of the human milk fat globule membrane: production and
reaction with cells in culture. Int J Cancer 28: 17–21
Tramontano A, Chothia C, Lesk AM (1990) Framework residue 71 is a
major determinant of the position and conformation of the second
hypervariable region in the VH domains of immunoglobulins. J Mol Biol
215: 175–182
Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T,
Tanaka S, Irimura T, Kim YS, Sato E (1998) Expression of MUC1 and
MUC2 mucins in gastric carcinomas: its relationship with the prognosis
of the patients. Clin Cancer Res 4: 2605–2614
Verhoeyen ME, Saunders JA, Price MR, Marugg JD, Briggs S, Broderick EL,
Eida SJ, Mooren AT, Badley RA (1993) Construction of a reshaped
HMFG1 antibody and comparison of its fine specificity with that of the
parent mouse antibody. Immunology 78: 364–370
Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-
Wittke U, Pluckthun A (1999) High thermal stability is essential for
tumor targeting of antibody fragments: engineering of a humanized anti-
epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain
Fv fragment. Cancer Res 59: 5758–5767
Xiang J, Sha Y, Jia Z, Prasad L, Delbaere LT (1995) Framework residues 71
and 93 of the chimeric B72.3 antibody are major determinants of the
conformation of heavy-chain hypervariable loops. J Mol Biol 253: 385–390
Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor
penetration of a single-chain Fv and comparison with other immuno-
globulin forms. Cancer Res 52: 3402–3408
VH-71 and stability of a humanised anti-MUC1 scFv
J Krauss et al
1870
British Journal of Cancer (2004) 90(9), 1863–1870 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s